FindTrial
Sign In

BRAFV600E immunoprofiling in precancerous and cancerous lesions of the breast by immunohistochemistry and to study its association with clinicopathological features.

Immunoprofiling of BRAFV600E in precancerous and cancerous lesions of breast by immunohistochemistry and its association with clinicopathological features.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/06/053430
Enrollment
45
Registered
2023-06-01
Start date
Unknown
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C509- Malignant neoplasm of breast of unspecified site

Interventions

None listed

Sponsors

Indian council of medical research
Lead Sponsor
Department of pathology
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: The cases diagnosed on biopsy or surgical specimen of breast cancer.

Exclusion criteria

Exclusion criteria: 1. Breast Biopsy with inflammatory histomorphology. 2. The biopsy without representative histomorphology of precancerous and cancerous lesion. 3. Deficient clinical data and details.

Design outcomes

Primary

MeasureTime frame
Primary Outcome:To study the expression of BRAFV600E in relation to prognosis and predictions to outcome. Timepoint: 2 years—

Secondary

MeasureTime frame
Seconday outcome:This study will determine the significance of immunoprofiling of BRAFV600E in breast cancer. Timepoint: 2 years—

Countries

India

Contacts

Public ContactSimran Khan

Dattta Meghe institue of medical sciences,sawangi, meghe, wardha.

aravani@rediff.com9822684255

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026